Is Bio-Rad a good stock to buy?
Bio-Rad Laboratories has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Is Bio-Rad publicly traded?
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets….Bio-Rad Laboratories.
|Bio-Rad Laboratories is based in Hercules, California, located along the Bay.|
|Traded as||NYSE: BIO (Class A) S&P 500 component|
Why is Bio-Rad stock down?
Shares in Bio-Rad dropped 16.8 percent for the five-day trading period ended Tuesday. The firm’s shares took a hit due to an underwhelming financial forecast during its fourth-quarter conference call last week (see related article, this issue), and a drop in stocks across the board.
When did Bio-Rad go public?
1966. Bio-Rad holds its Initial Public Offering and sells 40,000 shares at $3.50 a share.
Is Bio-Rad undervalued?
According to the company’s typical P/E ratio relation to the S&P 500’s P/E ratio, BIO is undervalued.
Why is Bio-Rad stock so high?
Demand Boost Increased Bio-Rad Labs Revenues The testing equipment and software for such endeavors is Bio-Rad’s bread and butter. This significantly increased demand for its products, which gave it a big boost in sales revenue, specifically in the company’s PCR and Droplet Digital PCR equipment.
Who are Bio-Rad competitors?
Bio-Rad Laboratories competitors include Agilent Technologies, Roche and Danaher.
Does Bio Rad own Sartorius?
The answer is yes. The remaining 73% of Sartorius is family-owned, and Bio-Rad intends to wholly acquire the company when the family trust expires in 2028.
What industry is Bio-Rad?
Description. Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments.